2021
DOI: 10.1007/s12072-021-10163-0
|View full text |Cite
|
Sign up to set email alerts
|

Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(12 citation statements)
references
References 24 publications
1
11
0
Order By: Relevance
“…We adopted the Paris II criteria in the present study, as they could predict overall survival, liver-related death, and future prevalence of symptoms in patients with PBC. 4,6 The percentage of patients who met the requirements in this study was approximately equivalent to that in previous reports; therefore, we believe that the results from this study are reproducible.…”
Section: Discussionsupporting
confidence: 84%
See 2 more Smart Citations
“…We adopted the Paris II criteria in the present study, as they could predict overall survival, liver-related death, and future prevalence of symptoms in patients with PBC. 4,6 The percentage of patients who met the requirements in this study was approximately equivalent to that in previous reports; therefore, we believe that the results from this study are reproducible.…”
Section: Discussionsupporting
confidence: 84%
“…23,24 These studies did not use the Paris II criteria, which have been reported to be the best for prognosis prediction, to determine treatment response. 4,6 We reported that prothrombin time % and AST were the independent predictors for the Paris II criteria; however, ROC was 0.695 and 0.669, respectively. 6 The AUC for data 1 and 2 was >0.8, sufficiently high for use in actual clinical practice.…”
Section: Discussionmentioning
confidence: 94%
See 1 more Smart Citation
“…As these studies aimed to predict the Barcelona, Paris I, or Toronto criteria, it is difficult to compare our results with theirs. However, previous reports have shown that Paris II criteria could predict OS, LRD, and newly developed symptoms in patients with PBC 16,17 . From these data, we deduced that our prediction model could be more useful than previous prediction models.…”
Section: Discussionmentioning
confidence: 67%
“…Primary biliary cholangitis (PBC) is a cholestatic disease with an autoimmune pathophysiology. Guidelines recommend treatment with weight‐based ursodeoxycholic acid (UDCA) as a standard first‐line therapy for this chronic inflammatory liver disease 9,11,17,23–25 . Treatment response at 12 months after initial UDCA treatment is recognized as a surrogate marker for early detection of high‐risk patients as per the guidelines.…”
Section: Introductionmentioning
confidence: 99%